The EMA recommends that the European Commission go ahead and approve Valneva’s vaccine for use within the Union. The vaccine is approved for people in the age range 18-50 years.
The vaccine is given in two doses at four-week intervals. It consists of dead particles of the coronavirus sars-cov-2, which means that people who receive the vaccine are not at risk of getting covid-19.
The EMA refers to a study conducted on almost 3,000 people over the age of 30. The study showed that Valneva’s vaccine led to the production of more antibodies than the comparative vaccine Vaxzevria from Astra Zeneca.
Valneva’s headquarters are located in France, although production takes place in Solna, Sweden, Austria and Scotland.
To date, six covid-19 vaccines have been approved in the EU.